Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Sorafenib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PASO
- 17 Feb 2017 Status changed from active, no longer recruiting to completed.
- 30 Mar 2013 Planned number of patients changed from 140 to 148 as reported by EudraCT.
- 13 Mar 2013 Planned end date changed from 1 Jan 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.